

KEY INVESTOR INFORMATION

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

Lyxor MSCI World Health Care TR UCITS ETF - C-EUR (the "Fund")

ISIN: LU0533033238 - A sub-fund of the investment company named MULTI UNITS LUXEMBOURG (the "Company") domiciled in Luxembourg. Managed by Lyxor International Asset Management S.A.S. ("LIAM")

Objectives and investment policy

The investment objective is to track both the upward and downward evolution of the MSCI WORLD HEALTH CARE Net Total Return Index (code Bloomberg : NDWUHC) ("Benchmark Index"), representative of healthcare companies from the Developed World markets.

MSCI's website (www.msci.com) contains more detailed information about the MSCI indexes.

The Fund seeks to achieve its objective via indirect replication by entering into an over-the-counter swap contract (financial derivative instrument, the "FDI").

The Fund may also invest in a diversified portfolio of international equities, whose performance will be exchanged against the performance of the benchmark Index via the FDI. Updated composition of the Fund holdings is available on www.lyxoretf.com.

In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the Fund, and might also be mentioned on the websites of the stock exchanges where the Fund is listed.

The share currency is the Euro (EUR).

- **Invested financial instruments:** FDI, international equities, UCITS, other financial instruments.
- **Dividend policy:** the Fund's amounts available for distribution (if any) shall not be distributed to Shareholders, but reinvested.
- **Net Asset Value:** is daily calculated providing that the relevant stock exchanges are open for trading and orders can be covered.
- **Redemptions:** investors are able to redeem their shares on the primary market every valuation day before 18:30 CET and sell their shares on the secondary market at any time during trading hours on the Fund listing places.

Risk and reward profile



The risk-return category shown above is based on the historical performance of the assets included in the Fund, or of its benchmark index. This risk estimate may therefore not represent a reliable indicator of future risk, and may be subject to change over time. The lowest category does not mean risk free investment.

Resulting from its exposure to the Benchmark Index, the Fund has been classified within category 5. Category 5 indicates that under normal market conditions a significant loss of capital is possible ; the value of your investment may change significantly and have above average daily upside or downside variation.

Main risks not covered by the above indicator which could lead to a decrease in the net asset value of the Fund and which the Fund is authorized to disclose in this document (for more details about risks, please refer to the Risk Profile section of the prospectus):

- **Counterparty risk:** the Fund is exposed to the risk of bankruptcy, or any other type of default of the counterparty related to any trading transaction entered into by the Fund.
- **Risk of using FDI:** in order to reach its investment objective, the Fund enters into over-the-counter FDI which provide the performance of the Benchmark Index. The FDI could be affected by various risks such as change in law or tax events.

Charges for this Fund

The charges you pay are used to pay the costs of running the Fund including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

For any additional information regarding charges, please refer to the relevant charges section of the Fund prospectus, available at www.lyxoretf.com.

One-off charges taken before or after you invest	
Entry Charge application on primary market only:	At most, the highest between (i) 50 000 Euros per subscription request and (ii) 5 % of the net asset value per share multiplied by the number of shares subscribed.
Exit Charge application on primary market only:	At most, the highest between (i) 50 000 Euros per redemption request and (ii) 5 % of the net asset value per share multiplied by the number of shares redeemed.
This is the maximum that might be taken out of your money before it is invested and before the proceeds of your investment are paid out. Investors can find out the actual entry charges and exit charges from their financial advisor or distributor. When investing on a stock exchange where the Fund is listed, no entry / exit charge do apply but other fees such as brokerage fees may apply.	
Charges taken from the Fund over a year.	
Ongoing charge:	0.30 %.
The ongoing charges figure shown here is an estimate of the charges. This estimate reflects the decrease in management fees effective from 1 June 2017. The figure shown here corresponds to the rate applicable after this date and will differ from the exact charges made during the whole year including the period before the change. The UCITS' annual report for each financial year will include detail on the exact charges made.	
Charges taken from the Fund under certain specific conditions	
Performance fee:	Not applicable.


Past performance

Past performances are not a reliable indicator of future results.

The performance is disclosed in Euro (EUR) and net of all fees charged to the Fund.

The Fund was created on 19 August 2010.

ANNUAL PERFORMANCE OF Lyxor MSCI World Health Care TR UCITS ETF - C-EUR (in %)



Practical information

- **Custodian:** Société Générale Bank & Trust.
- **Tax:** tax legislation applicable in the home Member State where the Fund is domiciled may impact investors.
- **Additional information:** the Fund's prospectus, net asset value and other share class information (if any), are available on www.lyxoretf.com.

Details of the remuneration policy are available on www.lyxor.com.

The prospectus, the details of the remuneration policy, the latest annual report and semi-annual report are also available in English or in French and free of charge upon request from Lyxor Asset Management, Client Servicing, 17, Cours Valmy, Tour Société Générale, 92800 Puteaux, FRANCE.

LIAM may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Fund.

The prospectus and periodic reports are prepared for the entire Company. The assets and liabilities of each sub-fund of the Company are segregated by law. If applicable, conversion rules between sub-funds (and related fees, if any) are detailed in the prospectus.

The Fund is authorized in Luxembourg and regulated by the CSSF.

LIAM is regulated by the *Autorité des marchés financiers* (the French Financial Markets Authority).

The key investor information is accurate and up to date as at 20 April 2018.